All In Biotech

Drug Trial Radar · NCT00229021

Doripenem in the Treatment of Complicated Lower Urinary Tract Infection or Pyelonephritis

A Multicenter, Double-Blind, Randomized, Phase 3 Study of Doripenem Verus a Comparator Antibiotic in the Treatment of Complicated Lower Urinary Tract Infection or Pyelonephritis

Last checked: Nov 20, 2026Latest source record: Jun 10, 2011 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 741 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

741

Actual

Start

Dec 2003

Primary completion

Not stated

Study completion Mar 2006

Sponsor

Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Johnson & Johnson (Janssen) (JNJ)
Sponsor type
Industry
Collaborators
Peninsula Pharmaceuticals, Inc.
First posted
Sep 29, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to compare the microbiological cure rate of doripenem versus a comparator antibiotic in the treatment of patients with complicated urinary tract infection or pyelonephritis. The study will also characterize the safety and tolerability of treatment with doripenem in patients with complicated urinary tract infection or pyelonephritis.

Conditions

  • Urinary Tract Infections
  • Pyelonephritis

Interventions

  • doripenumDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Microbiological response measured at test of cure visit at early follow-up.

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.